CD274 and neoplasm: Several biomarkers of the ICIs response are being investigated, including PD-L1 protein expression, tumor mutational burden, T cell infiltration transcriptomic subtypes, and T cell pathway activation [47], but these have not as yet been shown to accurately identify patients who are more likely to benefit from ICIs.